Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
111
datasets available to search
ShareScore release 0.9.0
Dataset results
111 results for “leiomyoma”
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
ClinicalTrials.gov study NCT02147158. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
ClinicalTrials.gov study NCT00971620. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
ClinicalTrials.gov study NCT02147197. IPD Sharing: Not stated. Countries: 1. Publications: 3.
IMMUNO-BIOCHEMICAL AND HISTOLOGICAL CHARACTERISTICS OF UTERINE LEIOMYOMA
<p> </p> <p><span>Лейомиома матки является распространенным гинекологическим заболеванием, которое поражает женщин различных возрастных групп, особенно в репродуктивном возрасте. Для изучения клинических характеристик и патофизиологических механизмов этого заболевания было проведено комплексное клиническое исследование с участием 120 женщин с диагнозом лейомиома матки в возрасте от 20 до 49 лет. Большинство участников составили женщины в возрасте от 40 до 49 лет (90 человек), среди которых значительное преобладание имели женщины узбекской национальности (106 женщин, 88,3%). Анализ уровня образования и рода занятий показал более высокую распространенность данной патологии среди женщин с средним специальным образованием (71,6%) и домохозяек (51,6%). Исследование также выявило сложный акушерский анамнез у участниц, из которых 14,2% сообщили о самопроизвольных выкидышах, 17,5% имели неразвивающуюся беременность, и 2,5% имели историю внематочной беременности. Основные жалобы у пациенток включали гиперполименорею (51,6%), боли в области таза и альгоменорею (36,7%), нарушения менструального цикла (59,2%), диспареунию (27,5%) и бесплодие (22,5%). Статистический анализ данных проводился с использованием как параметрических, так и непараметрических методов, выявив значительные клинические и лабораторные изменения. Например, у пациенток с лейомиомой матки были обнаружены повышенные уровни провоспалительных цитокинов, таких как IL-6 и TNF-α, а также факторов роста, таких как TGF-β2 и VEGF, что указывает на активные воспалительные и пролиферативные процессы.</span></p> <p><strong><span>Ключевые слова:</span></strong><span> лейомиома матки, самопроизвольные выкидыши, внематочные беременности, гиперполи менорея, боли в области таза, алгоменорея, нарушения менструального цикла, диспареуния, цитокины.</span></p>
Fig. 5 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 5. Nerolidol suppressed the protein and mRNA expression of ATM in rat leiomyoma cells. (A, B) ELT3 cells were treated with nerolidol for 48 h and were then harvested for the western blot analysis of phosphorylated ATM and total ATM (A) and for determining ATM mRNA expression using quantitative RT-PCR (B). GAPDH was used as the loading control. The inserted numbers in (A) represent the relative expression level compared to that of the vehicle control (indicated as 0 μM). (C, D, E, F) ELT3 cells were treated with the indicated concentrations of KU-55933, an ATM inhibitor, for 48 h, following which the cells were harvested for further analysis. (C) The expression levels of p-ATMser1981, total ATM, p-Aktser473, total Akt, CDK4, and CDK6 were determined using western blot analysis. β-Actin was used as the loading control. The inserted numbers in (C) represent the relative expression level compared to that of the vehicle control (indicated as 0 μM). (D, E) Cell cycle analysis was performed after propidium iodide staining and FACS, and the results were analyzed using the FlowJo software (D). The percentages of cells in each cell cycle phase are plotted in (E). (F) Cell proliferation was determined using the MTT assay. DMSO (0.1 %) was used as the vehicle control. The data are presented as relative percentage compared to that of the vehicle control. The p-value was calculated using one-way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05; **, p <0.01, and ***, p <0.001 compared to the control group.
Fig. 3 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 3. Nerolidol treatment led to the generation of intracellular ROS and impaired the mitochondrial membrane potential. (A) ELT3 cells were harvested after trypsin/EDTA treatment and then treated with 20 mM NAC, followed by DCFDA staining for 30 min. The cells were then treated with nerolidol for another additional 30 min, and DCF fluorescence was detected using flow cytometry. H2O2 was used as the positive control. The data were analyzed using the FlowJo software. (B, C) ELT3 cells were harvested and treated with nerolidol for 30 min. The cells were then stained with JC-1 dye for 15 min, followed by flow cytometry analysis. FCCP was used as the positive control. The data were analyzed using the FlowJo software. (B) The gated cells in the graphs indicate the cells with low mitochondrial membrane potential, and the quantitative results are plotted in (C). (D) ELT3 cells were treated with the indicated concentration of nerolidol for 48 h with or without co-treatment with 5 mM NAC. Cell proliferation was determined using the MTT assay. Ethanol (1 %) was used as the vehicle control. The data are presented as relative percentage compared to that of the vehicle control. (E) ELT3 cells were treated with the indicated concentration of nerolidol for 48 h with or without co-treatment with 20 μM ferrostatin-1. Cell proliferation was determined using the MTT assay. Ethanol (1 %) was used as the vehicle control. The data are presented as relative percentage compared to that of the vehicle control. The p-values were calculated using one-way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05; ***, p <0.001 compared to the vehicle control group (C). ***, p <0.001 compared to the nerolidol single treatment group (D, E).
Fig. 4 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 4. Treatment with nerolidol triggered DNA damage in rat leiomyoma cells. (A, B) ELT3 cells were harvested and treated with 100 μM nerolidol for 30 min, followed by determination of DNA damage using the comet assay. H2O2 (200 μM) was used as the positive control. The tail moments are indicated by red arrows in (A), as quantified using a live video imaging system, and dot plots show the mean ± SD in (B). (C, D, E) ELT3 cells were treated with 100 μM nerolidol for 1 h, followed by incubation with anti-p-γH2AXser139 antibody and FITC-conjugated secondary antibody. Nuclei were visualized using DAPI (blue). (C) P-γH2AXser139 expression was quantified using an automated imaging system. The relative positive cell number and the nuclear p-γH2AXser139 intensities are plotted in (D) and (E), respectively. The p-value was calculated using one-way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05; **, p <0.01, and ***, p <0.001 compared to the vehicle control group (1 % EtOH). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2. Nerolidol induced G1 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 2. Nerolidol induced G1 cell cycle arrest by downregulating Akt phosphorylation and cell cycle-related proteins. ELT3 cells were treated with the indicated concentrations of nerolidol for 48 h and were then harvested after trypsin/EDTA treatment. (A, B) For cell cycle analysis, the harvested cells were fixed with 70 % ethanol, followed by propidium iodide staining, and the DNA content was measured using flow cytometry. The results were analyzed using the FlowJo software (A). Blue, olive green, and green represent the G1, S, and G2/M phases, respectively. The percentage of each cell cycle phase was plotted in (B). The p-value was calculated using one-way ANOVA with Tukey's multiple post hoc test for each group.*, p <0.05; **, p <0.01, and ***, p <0.001 compared to the vehicle control group (1 % EtOH). (C) Total cellular protein content was measured, and the expression levels of phosphorylated Akt, total Akt, cyclin D1, CDK4, and CDK6 were determined using western blot analysis. β-Actin was used as the loading control. The inserted numbers in (C) indicate the relative expression level compared to that of the vehicle control (indicated as 0 μM). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 1 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 1. Nerolidol inhibited the proliferation of rat leiomyoma cells. ELT3 cells were seeded in 24-well plates and treated with the indicated concentrations of nerolidol for 48 h. (A) Images were captured under an inverted microscope at 100 × magnification. (B) The cells were trypsinized, and the number of viable (upper panel) or dead (lower panel) cells was counted after staining with trypan blue with a hemocytometer. (C) Cell proliferation was also determined using the MTT assay. Ethanol (1 %) was used as the vehicle control, which is indicated as 0 μM. The data are presented as relative percentage compared to the vehicle control. The p-value was calculated using one way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05 and ***, p <0.001 compared to the vehicle control group. The IC50 values were calculated using the IC50 Calculator (https://www.aatbio.com/tools/ic50-calculator).
Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)
ClinicalTrials.gov study NCT00332033. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry
ClinicalTrials.gov study NCT02100904. IPD Sharing: NO. Countries: 1. Publications: 1.
CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
ClinicalTrials.gov study NCT07106411. IPD Sharing: NO. Countries: 1. Publications: 17.
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
ClinicalTrials.gov study NCT02889848. IPD Sharing: NO. Countries: 1. Publications: 1.
Microwave Ablation for Leiomyoma
ClinicalTrials.gov study NCT04240262. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma
ClinicalTrials.gov study NCT01468402. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Effects of Simvastatin on Uterine Leiomyoma Size
ClinicalTrials.gov study NCT03400826. IPD Sharing: NO. Countries: 1. Publications: 0.
Supplementary files of 'Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma'
<p>Supplementary files of DOI https://doi.org/10.1038/s41586-021-03747-1</p>
A critical review of uterine leiomyoma with subsequent recurrence or metastasis: A multicenter study of 62 cases
<p><strong>Aim</strong>: Histopathologic diagnosis of a subset of uterine smooth muscle tumors is challenging. We report a critical review regarding the clinicopathological point of view of 62 cases of subsequently recurred or metastasized leiomyoma.</p> <p><strong>Methods</strong>: Medical records and glass slides of 62 cases of uterine smooth muscle tumor diagnosed as leiomyoma, which subsequently recurred or metastasized, were critically reviewed by pathologists specializing in gynecologic pathology and oncology. </p> <p><strong>Results</strong>: In 47 (75.8%) of 62 cases, the diagnosis of leiomyoma was confirmed, including 11 intravascular leiomyomatosis (IVL) and benign metastasizing leiomyoma (BML). In 29 cases (46.8%) laparoscopic surgery was performed, of which morcellator without a bag was employed in 23 cases. Fifteen cases (24.2%) appeared to be underestimated and were re-classified as smooth muscle tumor of uncertain malignant potential (STUMP), leiomyosarcoma, or other malignant mesenchymal tumors. Recurrences in 7 cases (11.3%) were interpreted to be a malignant transformation, and one Smooth muscle tumor of uncertain malignant potential (STUMP) recurred as STUMP. </p> <p><strong>Conclusion</strong>: The recurrence or metastasis in cases of "leiomyoma" is attributed to iatrogenic or under-evaluation of primary tumors, although a subset of cases is a rare example of biological progression.</p>
Correlation Between Serum Vitamin D3 and Incidence of Uterine Leiomyoma
ClinicalTrials.gov study NCT05151393. IPD Sharing: Not stated. Countries: 0. Publications: 14.
Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy
ClinicalTrials.gov study NCT01280045. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.